CD47-targeted bismuth selenide nanoparticles actualize improved photothermal therapy by increasing macrophage phagocytosis of cancer cells

In conclusion, Ab-PEG-Bi2Se3 may serve as an efficient PTT platform in combination with macrophage-mediated immunotherapy to improve antitumor efficacy.Graphical abstract
Source: Colloids and Surfaces B: Biointerfaces - Category: Biochemistry Source Type: research

Related Links:

Condition:   Renal Cell Carcinoma Intervention:   Drug: Fecal Microbiota Transplantation Sponsors:   Lawson Health Research Institute;   Academic Medical Organization of Southwestern Ontario Not yet recruiting
Source: - Category: Research Source Type: clinical trials
Condition:   Advanced Liver Cancer Interventions:   Drug: PD-1;   Drug: Sorafenib Sponsor:   Guangxi Medical University Recruiting
Source: - Category: Research Source Type: clinical trials
Publication date: Available online 14 November 2019Source: Seminars in Cancer BiologyAuthor(s): Radhakrishnan Vishnubalaji, Shaath Hibah, Ramesh Elango, Nehad M. AlajezAbstractSubstantial evolution in cancer therapy has been witnessed lately, steering mainly towards immunotherapeutic approaches, replacing or in combination with classical therapies. Whereas the use of various immunotherapy approaches, such as adoptive T cell therapy, genetically-modified T cells, or immune checkpoint inhibitors, has been a triumph for cancer immunotherapy, the great challenge is the ability of the immune system to sustain long lasting anti-...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 14 November 2019Source: Nano TodayAuthor(s): Xiaochen Liu, Dangge Wang, Pengcheng Zhang, Yaping LiAbstractCheckpoint blockade immunotherapy revolutionizes the field of cancer therapy, among which anti-programmed cell death (anti-PD) therapy is the most successful one in clinic. Despite the tremendous advancement, anti-PD therapy is still limited by barriers such as low response rate and immune related adverse effects (AEs), which are mainly resulted from poor intratumoral infiltration of cytotoxic T lymphocytes and off-tumor distribution of the anti-PD drugs. To address these issues, nano...
Source: Nano Today - Category: Nanotechnology Source Type: research
(UNC Lineberger Comprehensive Cancer Center) UNC Lineberger researchers discovered a biological signature that could help identify which triple negative breast cancers might respond to immunotherapy and other treatments.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
(University of California - San Francisco) In a breakthrough with important implications for the future of immunotherapy for breast cancer, UC San Francisco scientists have found that blocking the activity of a single enzyme can prevent a common type of breast cancer from spreading to distant organs.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Antitumor immunity has emerged as a favorable byproduct of radiation therapy (RT), whereby tumor-associated antigens released from irradiated cells unleash innate and adaptive attacks on tumors located both within and outside the radiation field. RT-induced immune responses further provide actionable targets for overcoming tumor resistance to RT (R-RT); immunotherapy (IT) with checkpoint inhibitors or Toll-like receptor (TLR) agonists can markedly improve, if not synergize with, RT in preclinical models, and several of these drugs are currently investigated as radiosensitizers in patients. In an unbiased chemical-genetic s...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Glioblastoma (GB) is the most common and aggressive primary brain tumor in adults and currently incurable. Despite multimodal treatment regimens, median survival in unselected patient cohorts is
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
AbstractImmune checkpoint blockers (ICB) have revolutionized cancer therapy. However, complete response is observed in a minority of patients and most patients develop immune-related adverse events (irAEs). These include colitis, which can be treated with anti-tumor necrosis factor (TNF) antibodies such as Infliximab. In a recent issue of the Journal for ImmunoTherapy of Cancer, Badran et al. reported that co-administering Infliximab together with ICB to five cancer patients prevents colitis recurrence, with four of them exhibiting overall disease stability. The basis for this treatment strategy stemmed from our pre-clinic...
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
ConclusionsThe epigenetic modificator EZH2 can suppress the expression of immune checkpoint inhibitor PD-L1 by directly upregulating the promoter H3K27me3 levels ofCD274 andIRF1 in hepatoma cells, and might serve as a potential therapeutic target for combination of immunotherapy for immune-activated HCC.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
More News: Biochemistry | Cancer | Cancer & Oncology | Immunotherapy | Nanotechnology | Study | Toxicology